Neoadjuvant cancer treatment with immunotoxin and checkpoint inhibitor combination

Neoadjuvant therapy with immunotoxins and immune checkpoint inhibitors effectively reduces tumor burden in glioblastoma and other EGFR-expressing tumors, enhancing survival and immune responses.

JP2024163118AInactive Publication Date: 2024-11-21DUKE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024124917
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-05-08
Filing Date
2024-07-31
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for glioblastoma and other tumors expressing the EGFR receptor offer poor survival prospects, with a median survival time of less than 15 months, necessitating the development of advanced and efficient therapeutic approaches.

Method used

A neoadjuvant therapy method involving the administration of immunotoxins, such as D2C7-IT, fused to a PE38 truncated Pseudomonas exotoxin, in combination with immune checkpoint inhibitors, to reduce tumor burden before surgical resection, followed by adjuvant or maintenance therapies.

Benefits of technology

This approach enhances tumor regression, improves overall and disease-free survival, decreases recurrence, and stimulates anti-tumor immune responses, offering improved therapeutic benefits compared to traditional treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163118000001_ABST
    Figure 2024163118000001_ABST
Patent Text Reader

Abstract

To provide an anti-tumor immunotherapy.SOLUTION: Provided is a method of treating a tumor in an individual by neoadjuvant therapy, where the individual has never undergone a resection of the tumor, the method comprising administering an immunotoxin, such as D2C7-immunotoxin (D2C7-IT), alone or in combination with an immune checkpoint inhibitor and an immunotoxin, and subsequently resecting the tumor. The method may further comprise administering the immune checkpoint inhibitor following the resection.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 672,150, filed May 16, 2018, U.S. Provisional Patent Application No. 62 / 675,263, filed May 23, 2018, and U.S. Provisional Patent Application No. 62 / 844,857, filed May 8, 2019, the contents of each of which are incorporated by reference in their entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with Government funding under Federal Grant Number: CA197264 awarded by the National Institutes of Health. The Government has certain rights in this invention. The present invention relates to the field of antitumor immunotherapy. In particular, the present invention relates to cancer treatment with immunotoxins by themselves or in combination with immune checkpoint inhibitors in neoadjuvant therapy. [Background technology]

[0002] Glioblastoma is the most aggressive malignant brain tumor among all primary brain and central nervous system tumors. Even with current standard treatments or newly developed drugs, the median survival time of patients with glioblastoma is less than 15 months. Therefore, there is an urgent need to develop advanced and efficient therapeutic approaches to improve the poor survival prospects of patients with glioblastoma and other tumors expressing the EGFR receptor. Summary of the Invention

[0003] According to one aspect of the present invention, a method of treating an individual's tumor by neoadjuvant therapy is provided. In this method, the individual has not previously undergone resection to treat the tumor (e.g., no surgical procedure to reduce tumor burden). The method of treating an individual's tumor by neoadjuvant therapy includes administering an effective amount of an immunotoxin, or an immunotoxin and an immune checkpoint inhibitor, the immunotoxin comprising an antibody or antigen-binding region thereof fused to a PE38 truncated Pseudomonas exotoxin, suitably a single-chain variable region antibody, and then the individual is treated to reduce tumor burden. In combination therapy, the immunotoxin and the immune checkpoint inhibitor can be administered to the individual in association, either simultaneously or sequentially. The tumor burden can be reduced, such as by surgical resection. Such tumor resection can be performed within a period ranging from two weeks to several months after administration of the immune checkpoint inhibitor and the immunotoxin. The immunotoxin comprises an antibody or antigen-binding region thereof, such as a single chain variable region antibody, fused to a PE38 truncated Pseudomonas exotoxin, the single chain variable region antibody having CDR1, CDR2, and CDR3 regions as set forth in SEQ ID NOs: 1-6 ("D2C7-IT"), or an antigen-binding fragment thereof.

[0004] According to another aspect of the present invention, a method for neoadjuvant immunotherapy of cancer is provided, comprising: a) administering to an individual having a tumor a therapeutically effective amount of a combination of immunotherapeutic agents, comprising an immunotoxin comprising an antibody or antigen-binding region thereof, e.g., a single-chain variable region antibody, fused to a PE38 truncated Pseudomonas exotoxin, in combination with another immunotherapeutic agent, such as an immune checkpoint inhibitor, the immunotherapeutic agent comprising an immunotoxin and an immune checkpoint inhibitor administered sequentially in a combination therapy; and b) treating the individual after taking the immunotherapeutic agent with an anti-cancer therapy selected from the group consisting of surgery, radiation therapy, and combinations thereof, effective to reduce the individual's tumor burden (e.g., tumor volume) (i.e., the immunotherapeutic agent is administered prior to the anti-cancer therapy). The immunotherapeutic agent may further comprise the addition of a pharmaceutically acceptable carrier. In one embodiment, the immunotoxin comprises a single chain variable region antibody fused to an exotoxin, the single chain variable region antibody having CDR1, CDR2, and CDR3 regions as set forth in SEQ ID NOs: 1-6 ("D2C7-IT"), or an antigen-binding fragment thereof.

[0005] In this method, the individual has not previously undergone a treatment to reduce tumor burden (e.g., no treatment to reduce tumor burden). An immune checkpoint inhibitor is administered to the tumor-bearing individual. An effective amount of an immunotoxin is administered to the individual, where the immunotoxin comprises a single chain variable region antibody capable of binding to EGFRwt and EGFRvIII (thus, the immunotoxin targets EGFRwt and EGFRvIII expressed on the cell surface of tumor cells), and the antibody is fused to a PE38 truncated Pseudomonas exotoxin. In one embodiment, the single chain variable region antibody has CDR1, CDR2, and CDR3 regions, or antigen-binding fragments thereof, as set forth in SEQ ID NOs: 1-6. Following administration of the neoadjuvant therapy comprising the immunotoxin, the individual undergoes surgery to remove the tumor, or other treatment to reduce tumor burden. Such reduction in tumor burden can occur over a period ranging from two weeks to several months after the neoadjuvant therapy. Optionally, the neoadjuvant therapy may further include administration of an immune checkpoint inhibitor to the tumor-bearing individual.

[0006] According to another aspect of the present invention, any one of the methods described herein can further comprise adjuvant therapy, comprising administering one or more of immunotoxins or immune checkpoint inhibitors targeting EGFRwt and EGFRvIII to an individual after tumor resection.For example, immune checkpoint inhibitors can be administered to an individual as necessary in maintenance therapy after resection.In another example, immunotoxins can be administered to an individual when tumor recurs after resection.

[0007] According to a further aspect of the present invention, there is provided neoadjuvant therapy of a tumor in an individual, and the use of an immunotoxin targeting EGFRwt and EGFRvIII, optionally including the use of an immune checkpoint inhibitor as a medicament or composition in neoadjuvant therapy of a tumor, wherein the tumor-bearing individual has not previously undergone resection to treat the tumor. In one aspect, the immunotoxin comprises a single chain variable domain antibody or antigen-binding fragment thereof fused to a PE38 truncated Pseudomonas exotoxin, the single chain variable domain antibody having CDR1, CDR2, and CDR3 regions as set forth in SEQ ID NOs: 1-6, and optionally comprising a therapeutically effective amount of an immune checkpoint inhibitor after the tumor has been treated with a therapeutically effective amount of an immunotoxin targeting EGFRwt and EGFRvIII, and after such treatment, the tumor is then resected or the tumor burden is otherwise reduced. Neoadjuvant therapy may further include one or more treatments including administering a therapeutically effective amount of an immunotoxin, or a therapeutically effective amount of an immune checkpoint inhibitor, or a combination thereof, following tumor resection (maintenance therapy).

[0008] Neoadjuvant therapy of a tumor in an individual is provided, comprising administering a therapeutically effective amount of an immunotoxin targeting EGFRwt and EGFRvIII to the tumor-bearing individual who has not previously undergone treatment to reduce tumor burden. The method may further comprise administering an effective amount of an immune checkpoint inhibitor to the tumor-bearing individual, administered prior to the treatment to reduce tumor burden. In one embodiment, the immunotoxin comprises a single chain variable region antibody fused to a PE38 truncated Pseudomonas exotoxin, the single chain variable region antibody having CDR1, CDR2, and CDR3 regions as set forth in SEQ ID NOs: 1-6, or antigen-binding fragments thereof. In another embodiment, the tumor is treated with either an immunotoxin or a combination of an immunotoxin and an immune checkpoint inhibitor, and then the tumor is resected. Neoadjuvant therapy provides improved therapeutic benefit compared to adjuvant therapy using an immunotoxin alone or a combination of an immunotoxin and an immune checkpoint inhibitor. Therapeutic benefits may include one or more of: reduced inflammation around the tumor site (pre- and / or post-resection), improved overall survival, improved disease-free survival, reduced likelihood of recurrence (in the primary organ and / or distant recurrence), reduced incidence of metastatic disease, and increased anti-tumor immune response, or improved overall objective response rate using response evaluation criteria known to those of skill in the art and appropriate for the type of cancer being treated (e.g., for lymphomas, see Cheson et al., 2014, J. Clin. Oncology 32 (27):3059-3067; for solid non-lymphoid tumors, see Response Evaluation Criteria in Solid Tumors (RECIST)). These and other aspects will become apparent to those of skill in the art upon reading this specification and will provide the art with new therapeutic regimens for treating cancer. [Brief description of the drawings]

[0009] [Figure 1]Figure 1 shows the in vivo efficacy of D2C7-IT + (αCTLA-4 or αPD-1) mAb combination therapy in subcutaneous CT2A-D2C7 glioma-bearing C57BL / 6 immunocompetent mice. Figure 1 shows percent survival in relation to days (where applicable) up to 100 days post-implantation for all treatment groups (D2C7-IT + αCTLA-4, D2C7-IT + αPD-1, αCTLA-4, αPD-1, D2C7-IT, vehicle control). [Diagram 2] FIG. 2 is a graph showing tumor volume in relation to days after tumor implantation in mice treated with PBS without subsequent tumor resection (-■-, PBS+no resection), mice treated with D2C7-IT without subsequent tumor resection (-▲-, D2C7-IT+no resection), mice treated with PBS with subsequent tumor resection (-▼-, PBS+with resection), and mice treated with D2C7-IT with subsequent tumor resection (-◆-, D2C7-IT+with resection). [Diagram 3] FIG. 3 shows percent survival of subcutaneous CT2A-D2C7 glioma-bearing C57BL / 6 immunocompetent mice in relation to days post-implantation up to day 80 (if applicable) for all treatment groups (vehicle control, D2C7-IT, D2C7-IT+αPD-1, D2C7-IT+αPD-L1, D2C7-IT+αTim-3, D2C7-IT+αLag-3, and D2C7-IT+αCD73). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The present inventors developed a targeted immunotoxin (IT), D2C7-(scdsFv)-PE38KDEL (D2C7-IT, SEQ ID NO: 5), by fusing a single-chain variable fragment (scFv) from the D2C7 monoclonal antibody (mAb) with Pseudomonas exotoxin A (PE), optionally fused to the KDEL peptide. D2C7-IT reacts with both wild-type epidermal growth factor receptor (EGFRwt) and EGFR mutant III (EGFRvIII), two proteins overexpressed in glioblastoma. The potent antitumor effect of D2C7-IT is mediated through PE in an orthotopic glioma xenograft model in immunodeficient mice. In addition to direct tumor cell killing, immunotoxin monotherapy induces a secondary antitumor immune response through the engagement of T cells. Improved and synergistic results are observed when immunotoxins are administered in combination regimens with immune checkpoint inhibitors in neoadjuvant therapy.

[0011] Other moieties that can be attached to antibodies include those that provide additional beneficial properties. For example, the KDEL (lys-asp-glu-leu) tetrapeptide can be added to the carboxy terminus of a protein to result in retention in the endoplasmic reticulum. Mutants such as DKEL, RDEL, and KNEL that function similarly can also be used. The single chain variable region antibodies described herein were derived from the D2C7 monoclonal antibody. Other antibody derivatives that contain the antigen-binding region of the D2C7 antibody can also be useful in the methods described herein. These antigen-binding regions or fragments of the antibodies and single chain variable region antibodies described herein that maintain the antigen-binding ability of the D2C7 monoclonal antibody can also be useful in the methods that include fragments of the D2C7 antibody, such as fragments of the single chain variable region antibodies, and fragments of the D2C7 antibody, such as the single chain variable region antibodies described herein. Other antigen-binding regions can include Fab, scFv, and small antibodies that contain single domains or fewer than all six CDRs. For use in the methods described herein, the immunotoxin comprises a single chain variable region antibody fused to a PE38 truncated Pseudomonas exotoxin. In some embodiments, the single chain variable region antibody has CDR1, CDR2, and CDR3 regions as set forth in SEQ ID NOs: 1-6, or an antigen-binding fragment thereof. An "antigen-binding fragment thereof" refers to a peptide capable of specifically and selectively binding to EGFRwt and EGFRvIII that comprises two or more of the CDRs identified as SEQ ID NOs: 1-6, preferably three or more of the CDRs of SEQ ID NOs: 1-6, or four or more of the CDRs of SEQ ID NOs: 1-6, or five or more of the CDRs of SEQ ID NOs: 1-6. For example, an antigen-binding fragment thereof may comprise (a) the V of SEQ ID NO: 7, H (b) V of SEQ ID NO:9 L (c) the V chain of SEQ ID NOs: 7 and 9 linked by a suitable linker H and V L (d) both V of SEQ ID NO: 7 and 9 linked by a linker of SEQ ID NO: 8 H and V L (e) V chain, which retains the ability to specifically bind EGFRwt and EGFRvIII H CDR1 (SEQ ID NO: 1), V HCDR2 (SEQ ID NO: 2), V H CDR3 (SEQ ID NO: 3), and V L CDR1 (SEQ ID NO: 4), V L CDR2 (SEQ ID NO: 5), and V L (f) a peptide comprising SEQ ID NO:7-4 in sequence, and (g) any combination thereof. Any one of the antigen-binding fragments can be fused to a PE38 truncated Pseudomonas exotoxin, such as PE38KDEL (SEQ ID NO:10). One suitable example of an immunotoxin is provided in SEQ ID NO:5 (the DNA sequence encoding this immunotoxin is found in SEQ ID NO:12) or a sequence having at least 90% sequence identity to SEQ ID NO:5. By "selective" or "specific" it is meant that the single chain variable region antibody or fragment thereof can bind to EGFRwt and EGFRvIII (found on tumor cells) but not other receptors found on normal cells.

[0012] Tumors that are amenable to treatment are any tumors that react with the D2C7 antibody or antigen-binding fragment thereof. These include, but are not limited to, tumors in which at least one EGFRvIII allele is present. These are found in breast, head and neck, brain, glioblastoma multiforme, astrocytoma, lung, or other tumors. It may be desirable to measure the presence of such alleles prior to treatment. This can be done using oligonucleotide-based techniques such as PCR, or using immunological techniques such as immunohistochemistry. It may be desirable to measure the amount, fraction, ratio, or percentage of cells in the tumor that express EGFR and / or EGFRvIII. The more cells that express EGFR on their surface, the more beneficial such antibody therapy may be. Even tumors that express little or no EGFRvIII may be treated due to the ability of the antibody to bind wild-type EGFR. Optionally, tumors may be examined prior to treatment for reactivity with the D2C7 antibody. The immunotoxin itself may be used as an immunohistochemical agent before, during, or after treatment. A secondary reagent may be used with the immunotoxin for detection. The secondary reagent can, for example, recognize the Pseudomonas component of the immunotoxin.

[0013] Immunotoxin can be administered by any technique known in the art.To avoid the cytotoxicity of normal tissue expressing EGFR, compartmentalized delivery may be desirable.Suitable compartmentalized delivery methods include, but are not limited to, delivery to brain, delivery to surgically created tumor resection cavity, delivery to natural tumor cyst, and delivery to tumor parenchyma.

[0014] The tumors that can be treated by the method of the present invention are any tumors that express epidermal growth factor receptor (EGFR), whether wild type, EGFRvIII, or other mutants.Preferably, the tumor expresses the receptor in amounts that far exceed the expression by normal tissue.The mechanism of high level expression may be due to genetic amplification or other changes, whether genetic or epigenetic.Exemplary tumors that can be treated include, but are not limited to, malignant glioma, breast cancer, head and neck squamous cell carcinoma, and lung cancer.

[0015] Blockade of T cell immune checkpoint receptors can be performed on any such target, including but not limited to PD-1, PD-L1, TIM-3, LAG-3, CTLA-4, and CSF-1R, as well as combinations of such checkpoint inhibitors. Immune checkpoint receptors can be present on immune cells, such as but not limited to T cells, monocytes, microglia, and macrophages. Agents that effect immune checkpoint blockade can be small chemicals or polymers, antibodies, antibody fragments, single-chain antibodies, or other antibody constructs, including but not limited to bispecific antibodies and diabodies.

[0016] The immune checkpoint inhibitor that can be used according to the present invention is any immune checkpoint inhibitor that disrupts the inhibitory interaction between cytotoxic T cells and tumor cells. These include, but are not limited to, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA4 antibodies, anti-LAG-3 antibodies, and / or anti-TIM-3 antibodies. Checkpoint inhibitors approved in the United States include atezolizumab, ipimilumab, pembrolizumab, and nivolumab. Others in phase 3 clinical trials include tislelizumab. The inhibitor does not have to be an antibody, but can be a small molecule or other polymer. If the inhibitor is an antibody, it can be polyclonal, monoclonal, fragment, single chain, or other antibody mutant construct. The inhibitors can target any immune checkpoint known in the art, including, but not limited to, CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, and ligands of the B-7 family. A combination of inhibitors for a single target immune checkpoint or a combination of different inhibitors for different immune checkpoints can be used. In addition, blockade of CSF-1R can be used in combination with or as an alternative to immune checkpoint inhibitors to ensure the generation of strong and sustained immunity that effectively eliminates distant metastases and recurrent tumors. Antibodies specific to CSF-1R or drugs that inhibit or block CSF-1R can be used for this purpose, including, but not limited to, emactuzumab and AMG820. Checkpoint inhibitors are commercially available and known in the art.For example, tremelimumab, an anti-CTL4 antibody, is available from MedImmune (AstraZeneca) and is described in, among others, U.S. Pat. No. 6,682,736 and European Patent No. 1,141,028; atezolizumab, an anti-PD-L1 antibody, is available from Genentech, Inc. (Roche) and is described in, among others, U.S. Pat. No. 8,217,149; ipimilumab, an anti-CTLA-4 antibody, is available from Bristol-Myers Squibb Co. and is described in, among others, U.S. Pat. Nos. 7,605,238, 6,984,720, 5,811,097, and European Patent No. 1,212,422; pembrolizumab, an anti-PD-1 antibody, is available from Merck and Co and is described in U.S. Patent Nos. 8,952,136, 8,354,509, 8,900,587 and EP 2,170,959; the anti-PD-1 antibody nivolumab is available from Bristol-Myers Squibb Co and is described in U.S. Patent Nos. 7,595,048, 8,728,474, 9,073,994, 9,067,999, 8,008,449, and 8,779,105; and tislelizumab is available from BeiGene and is described in U.S. Patent No. 8,735,553.

[0017] Examples of inhibitors of CSF-1R that can be used in combination therapy with immunotoxins include, but are not limited to, the following agents in clinical development: PLX3397, PLX486, RG7155, AMG820, ARRY-382, FPA008, IMC-CS4, JNJ-40346527, and MCS110. These CSF-1R inhibitors are commercially available, such as emactuzumab (RG7155), a humanized monoclonal antibody that binds to the tyrosine kinase receptor colony-stimulating factor 1 receptor (CSF1R), available from Genentech / Roche, among others, and described in U.S. Patent Application Publication No. 20110165156, U.S. Patent Nos. 9499624, 9499626, and 9499625, and is an anti-CSF1 monoclonal antibody. AMG820 is available from Amgen and is described in patent no. 8182813, CSF-1R inhibitors PLX3397 (pexidartinib, 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)-3-pyridinyl]methyl}-2-pyridinamine) and PLX7486 are available from Plexxikon, and CSF1R kinase inhibitor ARRY-382 is available from Array and FPA008 (caviralizumab) is available from Five Prime Therapeutics and described in WO2016106180. The anti-CSF1R antibody IMC-CS4 is available from ImClone (a subsidiary of Eli Lilly) and described in WO2011123381. The anti-CSFR1 antibody JNJ-40346527 (small molecule 4-cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide, also known as edicotinib, is available from MedKoo. and the anti-M-CSF monoclonal antibody MCS110, also known as lacnotuzumab, is available from Novartis and is described in PCT Patent Publication WO2007016240A2.

[0018] In the neoadjuvant therapy method, a therapeutically effective amount of one or more immunotherapeutic agents (immunotoxins targeting EGFRwt and EGFRvIII, or the immunotoxins and immune checkpoint inhibitors) are administered before the individual undergoes a reduction in tumor burden. Typically, when two immunotherapeutic agents are used, the agents are administered within a few days of each other. For example, an immune checkpoint inhibitor is administered, followed by an immunotoxin 30, 28, 21, 14, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 day after administration of the immune checkpoint inhibitor. Alternatively, it may be advantageous to administer the immunotoxin before administering the immune checkpoint inhibitor, with the immune checkpoint inhibitor administered to the individual within a few days after taking the immunotoxin. Priming of a cytotoxic T lymphocyte response by the immunotoxin may take from about 5 to about 14 days. Administration of the checkpoint inhibitor may be beneficially initiated before, during, or after such a priming period. The immune checkpoint inhibitor may be administered by any suitable means known in the art for the particular inhibitor. These include intravenous, oral, intraperitoneal, sublingual, intrathecal, intracavity, intramuscular, and subcutaneous.

[0019] Any human tumor, including both pediatric and adult tumors, can be treated by this method of neoadjuvant therapy. The tumor can be present in any organ, such as the brain, prostate, breast, lung, colon, and rectum. Various types of tumors can be treated, including glioblastoma, medulloblastoma, carcinoma, adenocarcinoma, and the like. Other examples of tumors include adrenocortical carcinoma, anal carcinoma, appendix carcinoma, grade I (anaplastic) astrocytoma, grade II astrocytoma, grade III astrocytoma, grade IV astrocytoma, atypical teratoid / rhabdoid tumor of the central nervous system, basal cell carcinoma, bladder carcinoma, breast sarcoma, bronchial carcinoma, bronchioloalveolar carcinoma, cervical carcinoma, craniopharyngioma, endometrial carcinoma, uterine carcinoma, ependymoblastoma, ependymoma, esophageal carcinoma. , nasal neuroblastoma, Ewing's sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic cholangiocarcinoma, fibrous histiocytoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic tumor, gestational trophoblastic tumor, glioma, head and neck cancer, hepatocellular carcinoma, perihilar cholangiocarcinoma, hypopharyngeal cancer, intraocular melanoma, pancreatic islet cell tumor, Kaposi's sarcoma, Langerhans cell histiocytosis, large cell undifferentiated lung cancer, laryngeal Cancer, lip cancer, lung adenocarcinoma, malignant fibrous histiocytoma, medulloepithelioma, melanoma, Merkel cell carcinoma, mesothelioma, endocrine gland neoplasms, nasal cavity cancer, nasopharyngeal cancer, neuroblastoma, oral cavity cancer, oropharyngeal cancer, osteosarcoma, ovarian clear cell carcinoma, epithelial ovarian cancer, ovarian germ cell tumor, pancreatic cancer, papillomatosis, paranasal sinus cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumor, pineoblastoma, pituitary tumor, pleuropulmonary blastoma, renal cell Cancers of the respiratory tract with alterations in chromosome 15, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous non-small cell lung cancer, cervical squamous cell carcinoma, supratentorial primitive neuroectodermal tumor, testicular cancer, throat cancer, thymic carcinoma, thymoma, thyroid cancer, renal pelvis cancer, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms' tumor. Reduction of tumor burden refers to reducing the amount of tumor remaining by removing (e.g., surgery or "resection") or destroying (e.g., radiation therapy) all or a sufficient amount (debulking) of the tumor.

[0020] In addition to neoadjuvant therapy, which includes administering an immunotoxin targeting EGFRwt and EGFRvIII, or the immunotoxin and one or more immune checkpoint inhibitors, followed by surgically removing the tumor or reducing the tumor burden, the treatment of the individual may include one or more of chemotherapy, biological therapy, and radiation therapy. These modalities may be the current standard of care for the treatment of a particular human tumor. Neoadjuvant therapy may be administered before, during, or after the standard of care for treating the tumor. For example, a combination of immunotoxin and immune checkpoint inhibitor, which includes neoadjuvant therapy, may be administered after the failure of standard of care. If a combination is identified, it may be administered at separate times as two separate agents in a single combination regimen. Alternatively, two (or more) agents may be mixed and administered.

[0021] Immunotoxins can directly kill cancer cells that express high levels of target tumor antigens. Immunotoxin monotherapy can efficiently and directly destroy tumor cells expressing target epitopes such as PDPN, EGFRwt and / or its truncated mutant EGFRvIII in xenograft malignant brain tumor models in immunodeficient mice. Immunotoxin therapy can induce secondary antitumor immune responses in mouse glioma and other tumor models, which are different from the direct killing mechanism and require the cooperation of the immune system. Because malignant brain tumors are always heterogeneous masses, some tumor cells may be able to escape the direct target attack of immunotoxin therapy due to the lack of epitopes. For this reason, the secondary antitumor immune response stimulated by immunotoxins may play an important role in eliminating these tumor cells that are not directly targeted.

[0022] Recently, several studies have successfully demonstrated that tumor regression and improved survival were achieved in mouse glioma models by suppressing co-inhibitory molecules such as CTLA4 and PD1. Based on promising preclinical data, several clinical trials have begun to investigate the use of immune checkpoint inhibitors to treat malignant brain tumors, either as monotherapy or in combination with other antitumor agents.

[0023] However, malignant gliomas, including glioblastomas, have a relatively low mutation rate, which may produce fewer and less obvious tumor antigens, resulting in relatively poor basal immunogenicity compared to other tumor types that respond well to immunotherapy, such as melanoma and NSCLC. Therefore, the combination of targeted cytotoxic immunotherapy using immunotoxins and immune checkpoint inhibitors can provide synergistic antitumor effects.

[0024] A desirable combination therapy approach may have lower doses of targeted cytotoxic immunotherapy, including immunotoxins, to limit side effects and achieve long-term antitumor immunity. Immunotoxin therapy can efficiently and directly kill cancer cells expressing high levels of target antigens through its own cytotoxic mechanism. Cancer cells destroyed by local immunotoxin therapy release tumor antigens and / or other neoantigens. These antigens can then be presented to host T cells by APCs in local draining lymph nodes, which activates CTLs to migrate and eliminate remaining or recurrent tumor cells expressing specific tumor antigens at the tumor site. Throughout this process, various co-inhibitory checkpoint pathways between T cells and APCs, and / or between T cells and tumor cells, can trigger various mechanisms to inactivate T cells and regulate the continuation and strength of antitumor immunity. Immune checkpoint inhibitors, such as anti-CTLA4 and anti-PD1 mAbs, can block these immunosuppressive pathways and therefore increase tumor cell death caused by lymphocytes activated by targeted immunotoxin therapy. While the terms used in describing this invention are believed to be well understood by those of ordinary skill in oncology and medicine, the definitions provided herein are set forth to facilitate the description of the invention and to provide illustrative examples for the use of the terms. As used herein, the terms "a," "an," and "the" mean "one or more" unless the singular is expressly specified (e.g., the singular is expressly specified in a phrase such as "a single agent").

[0025] As used herein, the term "pharmaceutical acceptable carrier" refers to any compound or composition or carrier medium useful in any one or more of the administration, delivery, storage, stability of the compositions or combinations described herein. These carriers are known in the art and include, but are not limited to, diluents, water, saline, suitable vehicles (e.g., liposomes, microparticles, nanoparticles, emulsions, capsules), buffers, tracing agents, medical parenteral vehicles, excipients, aqueous solutions, suspensions, solvents, emulsions, detergents, chelating agents, solubilizing agents, salts, colorants, polymers, hydrogels, surfactants, emulsifiers, adjuvants, fillers, preservatives, stabilizers, oils, binders, disintegrants, absorbents, flavoring agents, and the like, as is commonly known in the pharmaceutical industry.

[0026] "Neoadjuvant therapy" is used herein to refer to anti-cancer therapy given to a tumor-bearing individual before that individual undergoes surgery to remove or reduce the tumor volume, or other treatment to reduce the tumor burden. Surgery can include total or partial resection of the tumor. Neoadjuvant therapy can result in a reduction in tumor burden that can facilitate subsequent resection. "Adjuvant therapy" is used herein to refer to the administration of cancer therapy after surgery to remove a tumor, or other method of reducing tumor burden has first been performed. "Maintenance therapy" is used herein to refer to a treatment regimen given to reduce the likelihood of disease progression or recurrence. Maintenance therapy can be provided for any length of time, depending on the evaluation of clinical parameters to assess response to treatment.

[0027] "Survival" is used herein to refer to an individual who is alive after treatment, including overall survival and disease-free survival. Survival is usually measured by the Kaplan-Meier method. Disease-free survival refers to an individual who has been treated and is alive without signs of cancer recurrence. Overall survival refers to an individual who is alive for a defined period of time. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples, which are provided herein for illustrative purposes only and are not intended to limit the scope of the invention. EXAMPLES

[0028] Example 1 A Phase I clinical trial will be conducted in tumor-bearing individuals using the immunotoxin D2C7-IT alone. The tumors were recurrent glioblastoma (GBM) and D2C7-IT was administered alone after tumor resection (adjuvant therapy). As of April 11, 2018, 41 patients had been treated in a Phase I dose-escalation study of a single intratumoral administration of D2C7-IT. 17 dose levels had been investigated (dose level 1 = 40 ng / mL). Dose level 17 (35,032 ng / mL) was identified as the dose limit. Additional patients are currently enrolled at dose level 16 (23,354 ng / mL) to confirm the median tolerated dose (Phase 2 dose). One patient at dose level 2 (80 ng / mL) remains disease-free with no additional treatment since D2C7-IT infusion after more than 32.7 months. Additionally, tumor responses without additional treatment have been observed in one patient treated at dose level 10 (2,050 ng / mL) and one patient treated at dose level 13 (6,920 ng / mL) at present >12.8 and >6.8 months post-treatment, respectively. Three patients have died at present, surviving for 23.7, 23.2, and 21.4 months. Two additional patients are surviving >18.9 and >18.2 months after intratumoral injection of D2C7-IT.

[0029] Example 2 Construction, expression, and purification of D2C7-(scdsFv)-PE38KDEL immunotoxin. The carboxyl terminus of the VH domain of D2C7 was linked to the amino terminus of the VL domain by a 15 amino acid peptide (Gly4Ser)3 linker. To obtain a stable IT, it is essential that the VH is located close to the VL during renaturation. This was achieved by mutating a single key residue in each chain to a cysteine ​​to form a stabilizing disulfide bond. Based on predictions using molecular modeling and empirical data with other dsFv recombinant ITs, we selected one amino acid in each chain to be mutated to a cysteine. These are residue 44 in framework region 2 (FR2) of VH and residue 100 in FR4 of VL (according to Kabat numbering). Therefore, we prepared an Fv containing both a peptide linker and a disulfide bond generated by a cysteine ​​residue replacing Ser44 of VH and Gly100 of VL. The D2C7(scdsFv) PCR fragment was then fused to DNA for domains II and III of Pseudomonas exotoxin A. The form of Pseudomonas exotoxin A used herein, PE38KDEL, has a modified C-terminus that increases its intracellular retention and subsequently enhances cytotoxicity. D2C7-(scdsFv)-PE38KDEL (DNA sequence SEQ ID NO: 12) was expressed in E. coli under the control of the T7 promoter and harvested as inclusion bodies.

[0030] Example 3 This example illustrates the adjuvant therapy of cancer. A mouse glioma line, CT-2A-dmEGFRvIII-Luc, overexpressing the D2C7-IT antigen mouse EGFRvIII (dmEGFRvIII) was established. The reactivity and therapeutic effect of D2C7-IT on CT-2A-dmEGFRvIII-Luc (tumor cells modified to express firefly luciferase or "FFLuc") cells were measured by flow cytometry and in vitro cytotoxicity assay, respectively. CT-2A-dmEGFRvIII-Luc was further analyzed for the expression of MHC class I and PD-L1 by flow cytometry. The in vivo efficacy of D2C7-IT or αCTLA-4 or αPD-1 monotherapy or combination therapy of D2C7-IT+αCTLA-4 or D2C7-IT+αPD-1 was evaluated in intracranial CT-2A-dmEGFRvIII-Luc glioma-bearing C57BL / 6 immunocompetent mice. For adjuvant treatment of the tumor, 60 mice were randomized into six treatment groups (vehicle control, D2C7-IT, αPD-1, αCTLA-4, D2C7-IT+αPD-1, and D2C7-IT+αCTLA-4, 10-12 mice / group) and treated with a total dose of 0.1 μg D2C7-IT / vehicle control by convection-enhanced delivery (CED) on days 6-9. Following implantation of CT-2A-dmEGFRvIII-Luc, five doses of 250 μg / dose of rat IgG2a isotype control antibody, αPD-1 antibody, or 100 μg / dose of αCTLA-4 antibody were delivered by intraperitoneal injection on days 6, 9, 12, 15, and 18. Antitumor response of intracranial (ic) tumors to treatment was assessed by percent increase in specific neurological endpoints (seizure activity, repetitive circling, or other subtle changes such as anorexia) or time to death. Animals were observed twice daily for signs of distress or onset of neurological symptoms, at which point mice were euthanized.Significant tumor growth delay (120% increase in median survival) and cure rate (4 / 12 mice) were observed in the D2C7-IT + αPD-1 combination therapy group, and significant tumor growth delay (80% increase in median survival) was observed in the D2C7-IT + αCTLA-4 combination therapy group (Figure 1).

[0031] This experiment was repeated with the following modifications: D2C7-IT was used in combination therapy with additional immune checkpoint inhibitors: anti-Tim-3 antibody (Figure 3, "αTim-3"), anti-Lag-3 antibody (Figure 3, "αLag-3"), anti-PD-L1 antibody (Figure 3, "αPD-L1") and anti-CD73 antibody (Figure 3, "αCD73"). Thus, the different combination therapies included D2C7-IT+αPD-1, D2C7-IT+αPD-L1, D2C7-IT+αTim-3, D2C7-IT+αLag-3, and D2C7-IT+αCD73. Also, dosing with immune checkpoint inhibitors was started before administration of D2C7-IT. In this regard, the immune checkpoint inhibitors were administered on days 3, 6, 9, 12, and 15, and D2C7-IT was administered on days 6 to 9 (as described above for D2C7-IT). As shown in Figure 3, the use of D2C7-IT in combination therapy with the immune checkpoint inhibitor αPD-L1 resulted in a significant increase in survival compared to other therapies and vehicle controls.

[0032] Example 4 This example describes neoadjuvant therapy of a tumor in an individual, comprising administering to the individual an effective amount of an immunotoxin (e.g., D2C7-IT) such that the tumor burden in the individual is reduced following the treatment. Female C57Bl6 / J (approximately 20 g; 7-8 weeks) mice were administered 3x10 IgG1-specific antibodies suspended in 100 μl of PBS. 6 CT2A-mEGFRVIII-D2C7-FFLuc cells were injected subcutaneously into the right flank. The implanted tumors were 50–100 mm 3Ten mice per treatment group were randomly selected to receive vehicle or neoadjuvant (D2C7-IT) with or without surgery to reduce tumor burden when tumors reached 100%. Test mice were treated with a single intratumoral (it) injection of 4 μg of D2C7-(scdsFv)-PE38KDEL diluted in 20 μl of PBS on day 12 (post-tumor inoculation). Control mice were handled in the same manner and treated with 20 μl of PBS only. On day 18 post-tumor inoculation and 7 days after neoadjuvant therapy, one set of control and neoadjuvant-treated mice was left untreated, while the second set of control and neoadjuvant-treated mice was injected with 0.5-1.5 mm 3 Tumors were measured three times a week with a handheld digital caliper, and tumor volumes were calculated in cubic millimeters using the formula: ([length] × [width2]) / 2. Tumor volumes between 1500 and 2000 mm were considered to be 100%. 3Animals were excluded from the study if they reached a tumor size of 100 or developed tumor ulcers (open wounds). As shown in Figure 2, 0 / 10 mice treated with PBS without subsequent tumor resection (-■-, PBS+no resection) had complete tumor regression. 0 / 10 mice treated with D2C7-IT without subsequent tumor resection (-▲-, D2C7-IT+no resection) had complete tumor regression. 2 / 10 mice treated with PBS with subsequent tumor resection (-▼-, PBS+with resection) had complete tumor regression. And 5 / 10 mice treated with D2C7-IT with subsequent tumor resection (-◆-, D2C7-IT+with resection) had complete tumor regression. Thus, a therapeutic benefit of increased tumor regression is observed when using a neoadjuvant approach to treat tumor-bearing individuals. Another example of a neoadjuvant therapy approach in this embodiment includes administration of an effective amount of an immune checkpoint inhibitor in combination (sequentially) with administration of an effective amount of an immunotoxin targeting EGFRwt and EGFRvIII, both administered prior to surgical removal of the tumor or other method to reduce tumor burden. Given that a neoadjuvant approach using D2C7-IT alone provides therapeutic benefit, the therapeutic benefit of using a neoadjuvant approach using D2C7-IT and an immune checkpoint inhibitor in combination with an immune checkpoint inhibitor will be apparent (in part because therapeutic benefit is observed from such combination therapy).

[0033] Example 5 A method of treating an individual with a tumor is provided, comprising administering a therapeutically effective amount of an immunotoxin targeting EGFRwt and EGFRvIII to the individual prior to surgical removal of the tumor, and then performing surgery to remove the tumor from the individual. This method of neoadjuvant therapy may further comprise administering a therapeutically effective amount of an immune checkpoint inhibitor to the individual with the tumor prior to tumor removal. For example, several days after treatment with anti-PD-1 antibody is started, an immunotoxin (D2C7-IT) is then administered intratumorally (for an individual with glioblastoma, intratumoral administration will be performed by infusion). One week after administration of the immunotoxin, another dose of an immune checkpoint inhibitor is administered to the individual (e.g., anti-PD-1 antibody, 240 mg). Three weeks after administration of the immunotoxin, another dose of an immune checkpoint inhibitor is administered to the individual (e.g., anti-PD-1 antibody, 240 mg). Four weeks after administration of the immunotoxin, the tumor is surgically removed. Five weeks after administration of the immunotoxin and one week after surgical resection, another dose of immune checkpoint inhibitor is administered to the individual (e.g., anti-PD-1 antibody, 240 mg). Seven, nine, eleven, and thirteen weeks after administration of the immunotoxin, another dose of immune checkpoint inhibitor is administered to the individual (e.g., anti-PD-1 antibody, 240 mg). Maintenance therapy including administration of immune checkpoint inhibitor can then proceed as medically warranted. For example, immune checkpoint inhibitor can be administered 17, 21, 25 weeks after administration of the immunotoxin, and every four weeks thereafter until about 101 weeks (e.g., anti-PD-1 antibody can be administered at 240 mg every two weeks for four months, and then at 480 mg every four weeks for up to two years).

[0034] Sequence Listing A text format sequence listing is submitted concurrently and is incorporated by reference as part of this application. The sequence listing provides the amino acid and nucleic acid sequences of the components of the immunotoxin. In particular, the sequence listing includes: H CDR1 (SEQ ID NO: 1), V H CDR2 (SEQ ID NO: 2), V H CDR3 (SEQ ID NO: 3), V L CDR1 (SEQ ID NO: 4), VL CDR2 (SEQ ID NO: 5), and V L The amino acid sequence of CDR3 (SEQ ID NO: 6) of the variable heavy chain (V H ) (SEQ ID NO: 7), the amino acid sequence of the variable light chain (V L The amino acid sequence of the V chain as shown in SEQ ID NO:8 (SEQ ID NO:9) H and V L The complete amino acid sequence of the immunotoxin D2C7-scdsFv-PE38KDEL (SEQ ID NO:5) is provided along with a suitable amino acid linker to link the chains, the nucleic acid sequence encoding the entire immunotoxin D2C7-scdsFv-PE38KDEL (SEQ ID NO:12), as well as the nucleic acid sequence of the D2C7-scdsFv portion (SEQ ID NO:13) and the nucleic acid sequence of the PE38KDEL portion (SEQ ID NO:14).

[0035] Those skilled in the art will readily appreciate that the present disclosure is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The disclosure described herein is presently representative of preferred embodiments, is exemplary, and is not intended as a limitation on the scope of the disclosure. Modifications thereof and other uses will occur to those skilled in the art and are encompassed within the spirit of the disclosure as defined by the scope of the claims.

[0036] It is not admitted that any reference, including any non-patent or patent literature cited herein constitutes prior art. It will be understood that, unless otherwise stated, reference to any document specifically herein does not constitute an admission that any of these documents form part of the general knowledge in the art in the United States or any other country. Any discussion of a reference states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinence of any of the documents cited herein. All references cited herein are incorporated by reference in their entirety, unless otherwise stated. In the event of any discrepancy between any definitions and / or explanations found in the cited references, the present disclosure shall control.

Claims

1. 1. A method of treating a tumor in a patient, comprising: (a) administering to an individual a therapeutically effective amount of an immunotoxin, or an immunotoxin and an immune checkpoint inhibitor, prior to surgical resection of the tumor; (b) reducing the tumor burden, optionally by performing surgery to remove the tumor or treating with radiation; and (c) optionally administering an immune checkpoint inhibitor to the individual following tumor resection; wherein the immunotoxin comprises an antibody or antigen-binding region thereof, which may be a single chain variable region antibody or antigen-binding fragment thereof, fused to a PE38 truncated Pseudomonas exotoxin, and the antigen-binding region comprises at least two CDR regions selected from the group consisting of SEQ ID NOs: 1-6.

2. The method of claim 1, wherein the antibody or antigen-binding region thereof comprises at least four CDR regions selected from the group consisting of SEQ ID NOs: 1-6.

3. The method of claim 1 or 2, wherein the antibody or antigen-binding region thereof comprises the six CDRs of SEQ ID NOs: 1-6.

4. The antibody or antigen-binding region thereof is a single chain variable region antibody and has a V H and V of SEQ ID NO:9 L The method according to any one of claims 1 to 3, comprising:

5. The method of any one of claims 1 to 4, wherein the PE38 truncated Pseudomonas exotoxin is fused to the KDEL peptide.

6. The method of any one of claims 1 to 5, wherein the antibody or antigen-binding region thereof is a single chain variable region antibody and comprises SEQ ID NO:

11.

7. The method according to any one of claims 1 to 6, wherein the tumor is a malignant glioma.

8. The method according to any one of claims 1 to 6, wherein the tumor is breast cancer.

9. The method according to any one of claims 1 to 6, wherein the tumor is head and neck squamous cell carcinoma.

10. The method according to any one of claims 1 to 6, wherein the tumor is lung cancer.

11. The method of any one of claims 1 to 6, wherein the immunotoxin is administered directly to the tumor.

12. The method of any one of claims 1 to 6, wherein the immune checkpoint is selected from the group consisting of PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, and CSF-1R.

13. The method of claim 12, wherein the checkpoint inhibitor is an anti-PD-1 antibody.

14. The method of claim 12, wherein the checkpoint inhibitor is an anti-PD-L1 antibody.

15. 13. The method of claim 12, wherein the checkpoint inhibitor is an anti-CTLA4 antibody.

16. The method of claim 12, wherein the checkpoint inhibitor is an anti-LAG-3 antibody.

17. The method of claim 12, wherein the checkpoint inhibitor is an anti-TIM-3 antibody.

18. The method of claim 12, wherein the checkpoint inhibitor is an anti-CSF-1R antibody.

19. The method of claim 12, wherein the checkpoint inhibitor is a small molecule inhibitor of CSF-1R.

20. The method of any one of claims 1 to 19, wherein in step (a), the immune checkpoint inhibitor administered prior to tumor resection is administered several days prior to administration of the immunotoxin.

21. 21. The method of any one of claims 1-20, further comprising administering multiple doses of an immune checkpoint inhibitor following tumor resection, wherein the multiple doses are administered days or weeks apart.